Matthew Anderton

Matthew Anderton is the Vice President of Clinical Operations for Rare Diseases at Ipsen, a role they have held since 2025. Previously, they served in various leadership positions in clinical operations at companies such as COMPASS Pathways, Wave Life Sciences, and Summit Therapeutics. Matthew also gained experience as a Clinical Research Associate and Clinical Study Support Manager at Servier and worked as a Postdoctoral Research Scientist at the University of Oxford. They hold a DPhil in Pharmacology from the University of Oxford and a BSc in Pharmacology from The University of Sheffield.